SERS-Based Assessment of MRD in Acute Promyelocytic Leukemia?
Acute promyelocytic leukemia (APL) is characterized by a unique chromosome translocation t(15;17)(q24;q21), which leads to the PML/RARA gene fusion formation. However, it is acknowledged that this rearrangement alone is not able to induce the whole leukemic phenotype. In addition, epigenetic process...
Main Authors: | , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-06-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2020.01024/full |
_version_ | 1819227210470391808 |
---|---|
author | Cristina Turcas Cristina Turcas Vlad Moisoiu Vlad Moisoiu Andrei Stefancu Ancuta Jurj Stefania D. Iancu Patric Teodorescu Patric Teodorescu Sergiu Pasca Sergiu Pasca Anca Bojan Anca Bojan Adrian Trifa Sabina Iluta Sabina Iluta Alina-Andreea Zimta Bobe Petrushev Mihnea Zdrenghea Mihnea Zdrenghea Horia Bumbea Daniel Coriu Delia Dima Nicolae Leopold Ciprian Tomuleasa Ciprian Tomuleasa Ciprian Tomuleasa |
author_facet | Cristina Turcas Cristina Turcas Vlad Moisoiu Vlad Moisoiu Andrei Stefancu Ancuta Jurj Stefania D. Iancu Patric Teodorescu Patric Teodorescu Sergiu Pasca Sergiu Pasca Anca Bojan Anca Bojan Adrian Trifa Sabina Iluta Sabina Iluta Alina-Andreea Zimta Bobe Petrushev Mihnea Zdrenghea Mihnea Zdrenghea Horia Bumbea Daniel Coriu Delia Dima Nicolae Leopold Ciprian Tomuleasa Ciprian Tomuleasa Ciprian Tomuleasa |
author_sort | Cristina Turcas |
collection | DOAJ |
description | Acute promyelocytic leukemia (APL) is characterized by a unique chromosome translocation t(15;17)(q24;q21), which leads to the PML/RARA gene fusion formation. However, it is acknowledged that this rearrangement alone is not able to induce the whole leukemic phenotype. In addition, epigenetic processes, such as DNA methylation, may play a crucial role in leukemia pathogenesis. DNA methylation, catalyzed by DNA methyltransferases (DNMTs), involves the covalent transfer of a methyl group (-CH3) to the fifth carbon of the cytosine ring in the CpG dinucleotide and results in the formation of 5-methylcytosine (5-mC). The aberrant gene promoter methylation can be an alternative mechanism of tumor suppressor gene inactivation. Understanding cancer epigenetics and its pivotal role in oncogenesis, can offer us not only attractive targets for epigenetic treatment but can also provide powerful tools in monitoring the disease and estimating the prognosis. Several genes of interest, such as RARA, RARB, p15, p16, have been studied in APL and their methylation status was correlated with potential diagnostic and prognostic significance. In the present manuscript we comprehensively examine the current knowledge regarding DNA methylation in APL pathogenesis. We also discuss the perspectives of using the DNA methylation patterns as reliable biomarkers for measurable residual disease (MRD) monitoring and as a predictor of relapse. This work also highlights the possibility of detecting aberrant methylation profiles of circulating tumor DNA (ctDNA) through liquid biopsies, using the conventional methods, such as methylation-specific polymerase chain reaction (MS-PCR), sequencing methods, but also revolutionary methods, such as surface-enhanced Raman spectroscopy (SERS). |
first_indexed | 2024-12-23T10:37:46Z |
format | Article |
id | doaj.art-70f64c9307704cc19ba944fb06a83e65 |
institution | Directory Open Access Journal |
issn | 2234-943X |
language | English |
last_indexed | 2024-12-23T10:37:46Z |
publishDate | 2020-06-01 |
publisher | Frontiers Media S.A. |
record_format | Article |
series | Frontiers in Oncology |
spelling | doaj.art-70f64c9307704cc19ba944fb06a83e652022-12-21T17:50:14ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2020-06-011010.3389/fonc.2020.01024539889SERS-Based Assessment of MRD in Acute Promyelocytic Leukemia?Cristina Turcas0Cristina Turcas1Vlad Moisoiu2Vlad Moisoiu3Andrei Stefancu4Ancuta Jurj5Stefania D. Iancu6Patric Teodorescu7Patric Teodorescu8Sergiu Pasca9Sergiu Pasca10Anca Bojan11Anca Bojan12Adrian Trifa13Sabina Iluta14Sabina Iluta15Alina-Andreea Zimta16Bobe Petrushev17Mihnea Zdrenghea18Mihnea Zdrenghea19Horia Bumbea20Daniel Coriu21Delia Dima22Nicolae Leopold23Ciprian Tomuleasa24Ciprian Tomuleasa25Ciprian Tomuleasa26Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, RomaniaDepartment of Hematology, “Ion Chiricuta” Institute of Oncology, Cluj-Napoca, RomaniaDepartment of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, RomaniaFaculty of Physics, Babeş Bolyai University, Cluj-Napoca, RomaniaFaculty of Physics, Babeş Bolyai University, Cluj-Napoca, RomaniaResearch Center for Functional Genomics and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, RomaniaFaculty of Physics, Babeş Bolyai University, Cluj-Napoca, RomaniaDepartment of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, RomaniaDepartment of Hematology, “Ion Chiricuta” Institute of Oncology, Cluj-Napoca, RomaniaDepartment of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, RomaniaResearch Center for Functional Genomics and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, RomaniaDepartment of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, RomaniaDepartment of Hematology, “Ion Chiricuta” Institute of Oncology, Cluj-Napoca, RomaniaDepartment of Hematology, “Ion Chiricuta” Institute of Oncology, Cluj-Napoca, RomaniaDepartment of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, RomaniaDepartment of Hematology, “Ion Chiricuta” Institute of Oncology, Cluj-Napoca, RomaniaMedfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, RomaniaMedfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, RomaniaDepartment of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, RomaniaDepartment of Hematology, “Ion Chiricuta” Institute of Oncology, Cluj-Napoca, RomaniaDepartment of Hematology, Carol Davila University of Medicine and Pharmacy, Bucharest, RomaniaDepartment of Hematology, Carol Davila University of Medicine and Pharmacy, Bucharest, RomaniaDepartment of Hematology, “Ion Chiricuta” Institute of Oncology, Cluj-Napoca, RomaniaFaculty of Physics, Babeş Bolyai University, Cluj-Napoca, RomaniaDepartment of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, RomaniaDepartment of Hematology, “Ion Chiricuta” Institute of Oncology, Cluj-Napoca, RomaniaResearch Center for Functional Genomics and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, RomaniaAcute promyelocytic leukemia (APL) is characterized by a unique chromosome translocation t(15;17)(q24;q21), which leads to the PML/RARA gene fusion formation. However, it is acknowledged that this rearrangement alone is not able to induce the whole leukemic phenotype. In addition, epigenetic processes, such as DNA methylation, may play a crucial role in leukemia pathogenesis. DNA methylation, catalyzed by DNA methyltransferases (DNMTs), involves the covalent transfer of a methyl group (-CH3) to the fifth carbon of the cytosine ring in the CpG dinucleotide and results in the formation of 5-methylcytosine (5-mC). The aberrant gene promoter methylation can be an alternative mechanism of tumor suppressor gene inactivation. Understanding cancer epigenetics and its pivotal role in oncogenesis, can offer us not only attractive targets for epigenetic treatment but can also provide powerful tools in monitoring the disease and estimating the prognosis. Several genes of interest, such as RARA, RARB, p15, p16, have been studied in APL and their methylation status was correlated with potential diagnostic and prognostic significance. In the present manuscript we comprehensively examine the current knowledge regarding DNA methylation in APL pathogenesis. We also discuss the perspectives of using the DNA methylation patterns as reliable biomarkers for measurable residual disease (MRD) monitoring and as a predictor of relapse. This work also highlights the possibility of detecting aberrant methylation profiles of circulating tumor DNA (ctDNA) through liquid biopsies, using the conventional methods, such as methylation-specific polymerase chain reaction (MS-PCR), sequencing methods, but also revolutionary methods, such as surface-enhanced Raman spectroscopy (SERS).https://www.frontiersin.org/article/10.3389/fonc.2020.01024/fullDNA methylationacute promyelocytic leukemiameasurable residual diseasedisease monitoringpatient follow-up |
spellingShingle | Cristina Turcas Cristina Turcas Vlad Moisoiu Vlad Moisoiu Andrei Stefancu Ancuta Jurj Stefania D. Iancu Patric Teodorescu Patric Teodorescu Sergiu Pasca Sergiu Pasca Anca Bojan Anca Bojan Adrian Trifa Sabina Iluta Sabina Iluta Alina-Andreea Zimta Bobe Petrushev Mihnea Zdrenghea Mihnea Zdrenghea Horia Bumbea Daniel Coriu Delia Dima Nicolae Leopold Ciprian Tomuleasa Ciprian Tomuleasa Ciprian Tomuleasa SERS-Based Assessment of MRD in Acute Promyelocytic Leukemia? Frontiers in Oncology DNA methylation acute promyelocytic leukemia measurable residual disease disease monitoring patient follow-up |
title | SERS-Based Assessment of MRD in Acute Promyelocytic Leukemia? |
title_full | SERS-Based Assessment of MRD in Acute Promyelocytic Leukemia? |
title_fullStr | SERS-Based Assessment of MRD in Acute Promyelocytic Leukemia? |
title_full_unstemmed | SERS-Based Assessment of MRD in Acute Promyelocytic Leukemia? |
title_short | SERS-Based Assessment of MRD in Acute Promyelocytic Leukemia? |
title_sort | sers based assessment of mrd in acute promyelocytic leukemia |
topic | DNA methylation acute promyelocytic leukemia measurable residual disease disease monitoring patient follow-up |
url | https://www.frontiersin.org/article/10.3389/fonc.2020.01024/full |
work_keys_str_mv | AT cristinaturcas sersbasedassessmentofmrdinacutepromyelocyticleukemia AT cristinaturcas sersbasedassessmentofmrdinacutepromyelocyticleukemia AT vladmoisoiu sersbasedassessmentofmrdinacutepromyelocyticleukemia AT vladmoisoiu sersbasedassessmentofmrdinacutepromyelocyticleukemia AT andreistefancu sersbasedassessmentofmrdinacutepromyelocyticleukemia AT ancutajurj sersbasedassessmentofmrdinacutepromyelocyticleukemia AT stefaniadiancu sersbasedassessmentofmrdinacutepromyelocyticleukemia AT patricteodorescu sersbasedassessmentofmrdinacutepromyelocyticleukemia AT patricteodorescu sersbasedassessmentofmrdinacutepromyelocyticleukemia AT sergiupasca sersbasedassessmentofmrdinacutepromyelocyticleukemia AT sergiupasca sersbasedassessmentofmrdinacutepromyelocyticleukemia AT ancabojan sersbasedassessmentofmrdinacutepromyelocyticleukemia AT ancabojan sersbasedassessmentofmrdinacutepromyelocyticleukemia AT adriantrifa sersbasedassessmentofmrdinacutepromyelocyticleukemia AT sabinailuta sersbasedassessmentofmrdinacutepromyelocyticleukemia AT sabinailuta sersbasedassessmentofmrdinacutepromyelocyticleukemia AT alinaandreeazimta sersbasedassessmentofmrdinacutepromyelocyticleukemia AT bobepetrushev sersbasedassessmentofmrdinacutepromyelocyticleukemia AT mihneazdrenghea sersbasedassessmentofmrdinacutepromyelocyticleukemia AT mihneazdrenghea sersbasedassessmentofmrdinacutepromyelocyticleukemia AT horiabumbea sersbasedassessmentofmrdinacutepromyelocyticleukemia AT danielcoriu sersbasedassessmentofmrdinacutepromyelocyticleukemia AT deliadima sersbasedassessmentofmrdinacutepromyelocyticleukemia AT nicolaeleopold sersbasedassessmentofmrdinacutepromyelocyticleukemia AT cipriantomuleasa sersbasedassessmentofmrdinacutepromyelocyticleukemia AT cipriantomuleasa sersbasedassessmentofmrdinacutepromyelocyticleukemia AT cipriantomuleasa sersbasedassessmentofmrdinacutepromyelocyticleukemia |